MedTrace Logo

Revefenacin in Acute Respiratory Insufficiency in COPD

NCT04315558 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 21

Last updated 2025-08-13

No results posted yet for this study

Summary

RARICO is a pragmatic, randomized, controlled, double-blinded, multi-center trial evaluating the safety and feasibility of nebulized revefenacin in comparison to nebulized ipratropium in patients with COPD and acute respiratory failure requiring invasive mechanical ventilation.

Conditions

  • COPD
  • Acute Respiratory Failure

Interventions

DRUG

Revefenacin Inhalation Solution [Yupelri]

nebulized drug comparison

DRUG

Ipratropium Bromide

nebulized drug comparison

Sponsors & Collaborators

Principal Investigators

  • Igor Z Barjaktarevic, MD, PhD · University of California, Los Angeles

  • Donald Tashkin, MD · University of California, Los Angeles

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
40 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-11-01
Primary Completion
2025-01-01
Completion
2025-01-01
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04315558 on ClinicalTrials.gov